Home » Posts tagged "上海夜生活IIS"

Does this FTSE 100 company have potential for big share price growth and income?

first_img Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Enter Your Email Address “This Stock Could Be Like Buying Amazon in 1997” Does this FTSE 100 company have potential for big share price growth and income? I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. See all posts by Andy Ross Andy Ross | Friday, 19th March, 2021 | More on: DGE GSK Simply click below to discover how you can take advantage of this.center_img Our 6 ‘Best Buys Now’ Shares Andy Ross owns shares in Diageo and AstraZeneca. The Motley Fool UK has recommended Diageo and GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. As a long-term investor, I’m interested in the total return my investments can provide. I want those returns to exceed the market and what I could achieve if I just invested passively in an index tracker fund. This is why I want to find high-growth smaller-caps, alongside FTSE 100 companies that can provide good income and growth.FTSE 100 company with improvement potentialGlaxoSmithKline (LSE: GSK) is a pharmaceuticals giant held by a lot of private and institutional investors. Its share price has been floundering, but there are catalysts for a re-rating on the horizon.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…The planned spin-out of its consumer business is the most obvious. The focus then on research and development (R&D) will put it on a potentially similar path to AstraZeneca, which has far outperformed GSK in recent years in terms of share price growth.Another would be acquisitions. GSK has already bought Tesaro to boost its oncology portfolio. Given the amount of catching up GSK needs to do, further acquisitions could boost the shares, provided they are strategic and reasonably priced. There’s some doubt over the dividend in the short term and it has been held flat for a few years. However, the discovery of blockbuster drugs (through internal R&D and acquisitions) could lead to dividend growth in the future.What are the potential downsides and reasons it might not multibag? One issue, of course, is that drugs don’t make it through trials. Another potential downside is that earnings suffer without the diversification of income that GSK currently has. That could put pressure on both the dividend and the share price, hitting shareholders with a double whammy.But I feel the GSK share price could be good value after its recent decline and I might add it to my portfolio for both income and growth.The Covid recovery shareDiageo (LSE: DGE) is a share that I already hold. I think the beverages group should bounce back strongly once lockdowns are completely lifted. That’s because it owns brands such as Johnnie Walker, Smirnoff and Guinness and a whole lot of other well-known alcoholic beverage names.When its trade customers — such as pubs, restaurants, and clubs — open again, there will be an immediate boost to earnings that has been missing for at least part of the last year. And its shares are up 60%+ over the last five years, even with the drop caused by Covid. To me that shows it can produce steady share price growth. The risks with this share are its valuation and the possibility of further Covid setbacks. Taking each in turn, the P/E is about 27, which is on the high side. But I’m happy to hold for the long term and think past performance could be replicated in the future as more people around the world enjoy drinks with strong brand names.I’d like to see the share price rebound as the economy reopens here in the UK and across other important markets (in Europe for example). However, new variations of Covid could delay that and hit Diageo’s share price.Overall though, I’m positive about Diageo and will keep it in my portfolio. I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Image source: Getty Images. last_img read more

Continue reading »